FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979301530> ?p ?o ?g. }

• W2979301530 abstract "Abstract Abstract 1726 Background: We previously reported that symptom burden among persons with ET and PV can be severe and adversely affect QOL. The presence of severe symptoms is linked to poor prognosis. There is considerable inter-subject heterogeneity regarding which symptoms are present in which subjects. No studies have empirically evaluated whether disease characteristics can be grouped in related symptom clusters. Using our previously validated 18 item Myeloproliferative Neoplasm Assessment Form (MPN-SAF) (Blood 2011;118:401–408) given in conjunction with the 9 item Brief Fatigue Inventory (BFI) (Cancer 1999;85:1186–1196), we sought to evaluate symptom burden by means of cluster analysis. Methods: Data was collected from an international cohort of subjects with MPNs including demographics, disease features and the completed BFI and MPN-SAF instruments. Surveyed symptoms included fatigue, early satiety, abdominal pain and discomfort, inactivity, headaches, concentration, dizziness, extremity tingling, insomnia, sexual difficulties, mood changes, cough, night sweats, pruritus, bone pain and fever on a 0 (absent) to 10 (worst-imaginable) scale. Development of symptom clusters was based on consideration of r-squared in hierarchical clustering using Ward linkage. Final cluster assignment was based on the nonhierarchical k-means method. Comparisons between symptom clusters were based on ANOVA and chi-squared tests. Results: Subject Demographic and Disease Characteristics: Data from 1,141 subjects with PV (N=519) and ET (N=622) was prospectively collected (Chinese 236, French 305, German 45, Italian 114, Dutch 191, English 56, Spanish 109, Swedish 85. Age (mean 59, range, 26–87) and gender (54% F) were typical. Five clusters were selected (Figure 1). Frequencies of prior bleeding, spleen size, anemia, presence of any lab abnormality, language, gender, and MPN type varied significantly between clusters (P<0.05). Cluster 1: The “Reduced Symptom” Profile (n=421 (37%; 60% ET, 40% PV) The largest cluster, subjects had increased complaints of sexual difficulties and fatigue. There was a slightly higher proportion of subjects with ET (60%) versus PV. There were fewer lab abnormalities (28% prevalence) and less prior bleeding (3%) compared to other clusters. Spleen size was smallest of the cluster (1 cm below costal margin). Cluster 2: The “Fatigue-dominant” Group (n=286 (25%; 56% ET, 44% PV)). Subjects in this cluster were predominantly female and had relatively few laboratory abnormalities (19%) than other cohorts. They are characterized by high severity of fatigue compared to end-organ symptoms. Symptom profiles emphasize fatigue, QOL and insomnia with some end-organ complaints. The cohor 63% of the cohort. Cluster 3: The “End-Organ Complaints” Group (n=210 (18%; 49% ET, 51% PV)). Male predominant (56%), subjects had mainly macro-vascular symptom complaints including sexual difficulties, insomnia, and overall QOL, with few microvascular related symptoms (low itching/night sweats). Cluster 4: “Cognitive Complaints” Cluster (n=110 (10%; 53% ET, 47% PV)). The smallest cluster and female predominant (64%), main complaints include fatigue, insomnia, loss of concentration, numbness, and sad mood. Cluster 5: The “Highly Symptomatic” Cluster (n=114 (10%; 44% ET, 56% PV)). Subjects had many cognitive complaints and symptoms correlated with severe micro-vascular abnormalities (pruritus) and or splenomegaly. This cluster had the largest spleen sizes (mean 3 cm), the highest prevalence of prior thrombosis (29%), and highest frequency of lab abnormalities (43%). Cognitive and end-organ complaints were rated as most severe. Conclusion: This analysis offers new means of evaluating persons with PV and ET utilizing symptom clusters. Laboratory and physical abnormalities differed significantly between symptom clusters indicating that our groupings likely result from biological alterations present in specific disease phenotypes. Future studies should investigate correlations between clusters and prognosis and genotype. Disclosures: Kiladjian: Celgene: Research Funding; Novartis: Honoraria, Research Funding; Shire: Honoraria. Roy:Novartis, BMS: Speakers Bureau. Harrison:Novartis: Honoraria, Research Funding, Speakers Bureau; YM Bioscience: Consultancy, Honoraria; Sanofi Aventis: Honoraria; Shire: Honoraria, Research Funding. Vannucchi:Novartis: Membership on an entity's Board of Directors or advisory committees. Passamonti:Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees. Mesa:Incyte: Research Funding; Lilly: Research Funding; Sanofi: Research Funding; NS Pharma: Research Funding; YM Bioscience: Research Funding." @default.
• W2979301530 created "2019-10-18" @default.
• W2979301530 creator A5002936841 @default.
• W2979301530 creator A5006360930 @default.
• W2979301530 creator A5007454329 @default.
• W2979301530 creator A5008609620 @default.
• W2979301530 creator A5009381933 @default.
• W2979301530 creator A5009383961 @default.
• W2979301530 creator A5010092183 @default.
• W2979301530 creator A5010776860 @default.
• W2979301530 creator A5012374853 @default.
• W2979301530 creator A5013149964 @default.
• W2979301530 creator A5013314518 @default.
• W2979301530 creator A5016216479 @default.
• W2979301530 creator A5018111458 @default.
• W2979301530 creator A5020573943 @default.
• W2979301530 creator A5021124944 @default.
• W2979301530 creator A5026078021 @default.
• W2979301530 creator A5028061272 @default.
• W2979301530 creator A5031949106 @default.
• W2979301530 creator A5033034382 @default.
• W2979301530 creator A5034779401 @default.
• W2979301530 creator A5036322035 @default.
• W2979301530 creator A5039057642 @default.
• W2979301530 creator A5042552477 @default.
• W2979301530 creator A5046436694 @default.
• W2979301530 creator A5046469980 @default.
• W2979301530 creator A5046772202 @default.
• W2979301530 creator A5046827092 @default.
• W2979301530 creator A5054976477 @default.
• W2979301530 creator A5055032084 @default.
• W2979301530 creator A5055401685 @default.
• W2979301530 creator A5058165733 @default.
• W2979301530 creator A5058909416 @default.
• W2979301530 creator A5060196258 @default.
• W2979301530 creator A5060309018 @default.
• W2979301530 creator A5064703568 @default.
• W2979301530 creator A5066308745 @default.
• W2979301530 creator A5066906876 @default.
• W2979301530 creator A5069072959 @default.
• W2979301530 creator A5070207000 @default.
• W2979301530 creator A5070758043 @default.
• W2979301530 creator A5071159965 @default.
• W2979301530 creator A5074458629 @default.
• W2979301530 creator A5075154206 @default.
• W2979301530 creator A5081564703 @default.
• W2979301530 creator A5082630637 @default.
• W2979301530 creator A5083385949 @default.
• W2979301530 creator A5088486180 @default.
• W2979301530 creator A5089433535 @default.
• W2979301530 creator A5090009905 @default.
• W2979301530 date "2012-11-16" @default.
• W2979301530 modified "2023-09-29" @default.
• W2979301530 title "Essential Thrombocythemia (ET) and Polycythemia Vera (PV) Symptom Burden: Phenotypic Cluster Analysis Among an International Sample of 1,141 ET and PV Patients" @default.
• W2979301530 doi "https://doi.org/10.1182/blood.v120.21.1726.1726" @default.
• W2979301530 hasPublicationYear "2012" @default.
• W2979301530 type Work @default.
• W2979301530 sameAs 2979301530 @default.
• W2979301530 citedByCount "0" @default.
• W2979301530 crossrefType "journal-article" @default.
• W2979301530 hasAuthorship W2979301530A5002936841 @default.
• W2979301530 hasAuthorship W2979301530A5006360930 @default.
• W2979301530 hasAuthorship W2979301530A5007454329 @default.
• W2979301530 hasAuthorship W2979301530A5008609620 @default.
• W2979301530 hasAuthorship W2979301530A5009381933 @default.
• W2979301530 hasAuthorship W2979301530A5009383961 @default.
• W2979301530 hasAuthorship W2979301530A5010092183 @default.
• W2979301530 hasAuthorship W2979301530A5010776860 @default.
• W2979301530 hasAuthorship W2979301530A5012374853 @default.
• W2979301530 hasAuthorship W2979301530A5013149964 @default.
• W2979301530 hasAuthorship W2979301530A5013314518 @default.
• W2979301530 hasAuthorship W2979301530A5016216479 @default.
• W2979301530 hasAuthorship W2979301530A5018111458 @default.
• W2979301530 hasAuthorship W2979301530A5020573943 @default.
• W2979301530 hasAuthorship W2979301530A5021124944 @default.
• W2979301530 hasAuthorship W2979301530A5026078021 @default.
• W2979301530 hasAuthorship W2979301530A5028061272 @default.
• W2979301530 hasAuthorship W2979301530A5031949106 @default.
• W2979301530 hasAuthorship W2979301530A5033034382 @default.
• W2979301530 hasAuthorship W2979301530A5034779401 @default.
• W2979301530 hasAuthorship W2979301530A5036322035 @default.
• W2979301530 hasAuthorship W2979301530A5039057642 @default.
• W2979301530 hasAuthorship W2979301530A5042552477 @default.
• W2979301530 hasAuthorship W2979301530A5046436694 @default.
• W2979301530 hasAuthorship W2979301530A5046469980 @default.
• W2979301530 hasAuthorship W2979301530A5046772202 @default.
• W2979301530 hasAuthorship W2979301530A5046827092 @default.
• W2979301530 hasAuthorship W2979301530A5054976477 @default.
• W2979301530 hasAuthorship W2979301530A5055032084 @default.
• W2979301530 hasAuthorship W2979301530A5055401685 @default.
• W2979301530 hasAuthorship W2979301530A5058165733 @default.
• W2979301530 hasAuthorship W2979301530A5058909416 @default.
• W2979301530 hasAuthorship W2979301530A5060196258 @default.
• W2979301530 hasAuthorship W2979301530A5060309018 @default.
• W2979301530 hasAuthorship W2979301530A5064703568 @default.
• W2979301530 hasAuthorship W2979301530A5066308745 @default.
• W2979301530 hasAuthorship W2979301530A5066906876 @default.
• W2979301530 hasAuthorship W2979301530A5069072959 @default.
• W2979301530 hasAuthorship W2979301530A5070207000 @default.
• W2979301530 hasAuthorship W2979301530A5070758043 @default.

• next